Related Experiment Video
Updated: Jun 27, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Anthracycline-induced cardiomyopathy
Ashley Simmons1, James L Vacek, David Meyers
1Division of Cardiovascular Diseases, University of Kansas School of Medicine, Kansas City, KS 66160, USA.
Abstract:
Anthracyclines are potent chemotherapeutic agents associated with 3 different forms of cardiomyopathy. Acute cardiomyopathy is seen within 3 months of drug exposure and may take the form of either a reversible myocarditis and pericarditis or an early-onset type and a late-onset type of chronic cardiomyopathy. Chronic anthracycline-induced cardiomyopathy is treated similarly to ischemic cardiomyopathies with beta-blockade and angiotensin-converting enzyme (ACE) inhibition. This review focuses on recent research regarding mechanisms of anthracycline-induced myocardial damage, the noninvasive imaging diagnosis of anthracycline-induced cardiomyopathy, and potential areas of future research regarding genetic screening and selecting individuals at increased risk, with consideration of prophylactic treatment with medications, specifically carvedilol and ACE inhibitors.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Myocarditis I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

